Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2/Phase 3
BOREAS
KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment
- NCT03662126 ↗
- Unknown
- Kartos Therapeutics, Inc.
- Deep
We haven't built an HCP commentary report on BOREAS (myelofibrosis relapsed or refractory to JAK inhibitor treatment) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on BOREAS so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| YouTube | 13 | |
| Podcasts | 12 | |
| X threads | 4 | |
| X videos | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase 2/3 Randomized, Controlled, Open-Label Study of KRT 232 in Subjects With Primary Myelofibrosis (PMF), Post Polycythemia Vera MF (Post-PV-MF), Or Post Essential Thrombocythemia MF (Post-ET-MF) Who Are Relapsed or Refractory to Janus Kinase (JAK) Inhibitor Treatment
- Phase
- Phase 2/Phase 3
- Status
- Unknown
- Conditions
- Primary Myelofibrosis (PMF); Post-Polycythemia Vera MF (Post-PV-MF); Post-Essential Thrombocythemia MF (Post-ET-MF)
- Interventions
- KRT-232; Best Available Therapy (BAT)
- Arms
- Part A Cohort 1 · Experimental
- Part A Cohort 2 · Experimental
- Part A Cohort 3 · Experimental
- Part A Cohort 4b · Experimental
- Part B Arm 1 KRT-232 · Experimental
- Part B Arm 2 Best Available Therapy · Active comparator
- Enrollment
- 385 (estimated)
- Primary outcomes
- (Part A Only) Spleen Volume Reduction (SVR)
- (Part B Only) Spleen Volume Reduction (SVR)
- Sponsor
- Kartos Therapeutics, Inc.
- Start
- Jan 15, 2019
- Primary completion
- Dec 31, 2023 (estimated)
- Results posted
- No
- Registry record
- NCT03662126 · updated Apr 28, 2023
Publications
linked from the registry- Al-Ali, H.K.; Delgado, R.G.; Lange, A.; Pluta, A.; McLornan, D.; Vachhani, P.; Damaj, G.L.; Jost, P.J.; Rejto, L.; Hus, M.; et al. KRT-232, A First-In-Class, Murine Double Minute 2 Inhibitor, for Myelofibrosis Relapsed or Refractory to Janus-Associated Kinase Inhibitor Treatment. Eha. Libr. 2020, 295035, S215